Zerigo Health (formerly Clarify Medical) provides at-home treatments for chronic skin conditions including psoriasis, vitiligo, and eczema, with narrowband ultraviolet B (NB-UVB) phototherapy.
The Zerigo Health ecosystem includes an FDA-approved, handheld Smart UVB Light Therapy device controlled by a smartphone app that calculates and personalizes dosages based on each patient's response. The cloud-based system monitors treatment progress and adherence through secure data sharing. Furthermore, Zerigo's technology combined with personalized coaching from ZerigoCare Guides aims to improve treatment adherence and outcomes compared to traditional phototherapy methods requiring frequent in-office visits.
Key customers and partnerships
In September 2022, Evernorth launched a pilot program offering the Zerigo solution through its Digital Health Formulary. Also, in September 2022, Artemis Health, a benefits analytics platform, announced a partnership, enabling clients to evaluate and manage the Zerigo solution's impact on outcomes, quality of life, and costs using Artemis' Console analytics tool.
Funding and financials
In October 2021, the startup raised USD 43 million in a Series B funding round led by 7wireVentures, allocated towards expanding its operations and market reach, particularly in the B2B2C segment consisting of health plans and employer-sponsored health insurance.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.